Arete Medical Technologies develops a patented digital health device for daily, at-home monitoring of chronic respiratory diseases like asthma and COPD. This device provides specialist, hospital-grade measurements accessible when and where patients experience symptoms. The platform aims to enable precision medicine and proactive health management for lung conditions, reducing preventable hospitalizations.
Funding
$280K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Managing chronic respiratory conditions like asthma and COPD often requires frequent and costly visits to specialist clinics for lung function testing. Existing diagnostic equipment is typically bulky, expensive, and confined to hospital settings, limiting accessibility for patients needing regular monitoring. This lack of convenient and affordable monitoring tools hinders proactive management and early intervention, leading to preventable hospitalizations and reduced quality of life.
Solution
Arete Medical Technologies offers a portable, web-connected device called the Respicorder that enables comprehensive respiratory monitoring in the home. The Respicorder combines three essential breathing tests—spirometry, impulse oscillometry, and FeNO measurement—into a single, user-friendly device. By providing hospital-grade measurements at a fraction of the cost of traditional equipment, the Respicorder empowers patients and their healthcare teams to proactively manage lung conditions with precision and prevention. The device facilitates early detection of respiratory distress, personalized treatment adjustments, and reduced reliance on emergency care, ultimately improving patient outcomes and reducing healthcare costs. The Respicorder serves as the foundation for a digital hub, integrating data and facilitating communication between patients and their healthcare providers for optimized respiratory care.
Target Audience
The primary target audience includes individuals with chronic respiratory conditions such as asthma and COPD, as well as healthcare providers seeking to improve patient outcomes and reduce healthcare costs through proactive and precision respiratory care.
Features
- Combines spirometry, impulse oscillometry, and FeNO measurement in a single portable device
- Web-connected for seamless data transfer and remote monitoring
- Enables frequent and convenient at-home respiratory assessments
- Provides hospital-grade measurements at a fraction of the cost of traditional equipment
- Facilitates early detection of respiratory distress and personalized treatment adjustments
- Supports a digital hub for integrated data management and communication between patients and healthcare providers